Program
GENSCI139
A development code. Also written as “GenSci139”.
Its studies are led by Changchun GeneScience Pharmaceutical.
Furthest: phase 1, since Sep 22, 20251 company-led study, 1 open or runningNext primary completion: Jul 7, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | 11 open or running | phase 1since Sep 22, 2025 | Sep 22, 2025 | Jul 7, 2028phase 1 · NCT07230977 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 22, 2025First study: phase 1 study in Advanced Solid TumorsFirst studyNCT07230977 · 280 planned · China
Ahead
- Jul 7, 2028Primary completion: phase 1 study in Advanced Solid TumorsNCT07230977
TargetBeta
“GenSci139 is a bispecific antibody drug conjugate targeting EGFR and HER2.”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| enozertinibrule | oric-pharmaceuticals | phase 2 | 3 |
| EGFR/HER2 Mutant-selective Inhibitor BH-30643rule | blossomhill-therapeutics | phase 2 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07230977Advanced Solid Tumors · China | 1 | Recruiting | Jul 7, 2028 | 280 |
How it is read
Names in the registry
- “GenSci139”, 1 entry
Codes read as this program: GENSCI139.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.